Capricor Therapeutics Stock Surges on Positive HOPE-3 Study Results

Capricor Therapeutics shares are trading higher after the company announced positive topline results from its pivotal Phase 3 HOPE-3 study of Deramiocel in Duchenne Muscular Dystrophy, demonstrating significant improvements in skeletal and cardiac functions.